Diagnostic value of MicroRNAs for urologic cancers: A systematic review and meta-analysis

Medicine (United States)

Volumn 94, Issue 37, 2015, Pages

  Ouyang, Hui ^a   Zhou, Yanzhao ^b   Zhang, Li ^a   Shen, Guanxin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 101; MICRORNA 107; MICRORNA 125B; MICRORNA 126; MICRORNA 133B; MICRORNA 141; MICRORNA 143; MICRORNA 145; MICRORNA 16; MICRORNA 1825; MICRORNA 195; MICRORNA 200A; MICRORNA 203; MICRORNA 205; MICRORNA 21; MICRORNA 210; MICRORNA 214; MICRORNA 221; MICRORNA 25; MICRORNA 26A; MICRORNA 30A 3P; MICRORNA 30C; MICRORNA 32; MICRORNA 361 3P; MICRORNA 375; MICRORNA 484; MICRORNA 628 5P; MICRORNA 99B; UNCLASSIFIED DRUG; UNINDEXED DRUG; TUMOR MARKER;

ARTICLE; ASIAN; BLADDER CANCER; CANCER DIAGNOSIS; CAUCASIAN; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ETHNICITY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; URINARY TRACT CANCER; METABOLISM; OBSERVATIONAL STUDY; UROLOGIC NEOPLASMS;

BIOMARKERS, TUMOR; HUMANS; MICRORNAS; OBSERVATIONAL STUDIES AS TOPIC; UROLOGIC NEOPLASMS;

EID: 84941965595     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001272     Document Type: Article

References (44)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
2. Chow TF, Youssef YM, Lianidou E, et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem. 2010;43:150-158.
3. Yi Z, Fu Y, Zhao S, et al. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer Res Clin Oncol. 2010;136:855-862.
4. Rolf O, Gohlke F. Endoprosthetic elbow replacement in patients with solitary metastasis resulting from renal cell carcinoma. J Shoulder Elbow Surg. 2004;13:656-663.
5. Van Der Horst G, Bos L, Van Der Pluijm G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res. 2012;10:995-1009.
6. Enokida H, Yamada Y, Yoshino H, et al. MicroRNAs detection in urine as diagnostic markers and predictors of recurrence of nonmuscle invasive bladder cancer. J Urol. 2012;187:e514.
7. Wilson M, Merkur H. Hematuria at laparoscopic hysterectomy: A 9-year review at Sydney West Advanced Pelvic Surgery, Australia. J Minim Invasive Gynecol. 2008;15:146-151.
8. Majid S, Dar AA, Saini S, et al. MicroRNA-1280 inhibits invasion and metastasis by targeting ROCK1 in bladder cancer. PLoS ONE. 2012;7:e46743.
9. Xu C, Zeng Q, Xu W, et al. miRNA-100 inhibits human bladder urothelial carcinogenesis by directly targeting mTOR. Mol Cancer Ther. 2013;12:207-219.
10. Yeh YM, Chuang CM, Chao KC, et al. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1alpha. Int J Cancer. 2013;133:867-878.
11. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10:704-714.
12. Gottardo F, Liu CG, Ferracin M, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007;25:387-392.
13. Faragalla H, Youssef YM, Scorilas A, et al. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn. 2012;14:385-392.
14. Leeflang MM, Deeks JJ, Gatsonis C, et al. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889-897.
15. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529-536.
16. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001;323:157-162.
17. Glas AS, Lijmer JG, Prins MH, et al. The diagnostic odds ratio: A single indicator of test performance. J Clin Epidemiol. 2003;56:1129-1135.
18. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293-1316.
19. Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird's methodology to perform multivariate random effects metaanalyses. Stat Med. 2010;29:1282-1297.
20. Ichimi T, Enokida H, Okuno Y, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009;125:345-352.
21. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol. 2010;28:655-661.
22. Hideki E, Chiyomaru T, Masahiko I, et al. MicroRNAs detection in urine samples from patients with urothelial carcinoma. Euro Urol, Supplements. 2010;9:47.
23. Wulfken LM, Moritz R, Ohlmann C, et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS ONE. 2011;6:e25787.
24. Yamada Y, Enokida H, Kojima S, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2011;102:522-529.
25. Miah S, Dudziec E, Drayton RM, et al. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer. 2012;107:123-128.
26. Puerta-Gil P, Garcia-Baquero R, Jia AY, et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 2012;180:1808-1815.
27. Redova M, Poprach A, Nekvindova J, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10:1479-5876.
28. Snowdon J, Boag S, Feilotter H, et al. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J. 2013;7:28.
29. Wang G, Chan ES, Kwan BC, et al. Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer. 2012;10:106-113.
30. Yun SJ, Jeong P, Kim WT, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol. 2012;41:1871-1878.
31. Zaravinos A, Radojicic J, Lambrou GI, et al. Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer. J Urol. 2012;188:615-623.
32. Adam L, Wszolek MF, Liu CG, et al. Plasma microRNA profiles for bladder cancer detection. Urol Oncol. 2013;31:1701-1708.
33. Mengual L, Lozano JJ, Ingelmo-Torres M, et al. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer. 2013;133:2631-2641.
34. Silva-Santos RM, Costa-Pinheiro P, Luis A, et al. MicroRNA profile: A promising ancillary tool for accurate renal cell tumour diagnosis. Br J Cancer. 2013;109:2646-2653.
35. Tolle A, Jung M, Rabenhorst S, et al. Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer. Oncol Rep. 2013;30:1949-1956.
36. Wach S, Nolte E, Theil A, et al. MicroRNA profiles classify papillary renal cell carcinoma subtypes. Br J Cancer. 2013;109:714-722.
37. Wang W, Li T, Li CW, et al. The analysis of miR-17-5p expression in urine for bladder cancer diagnosis. Med J Air Force. 2013;29:143-145154.
38. Zhao A, Li G, Peoc'h M, et al. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2013;94:115-120.
39. Chen X, Ruan A, Wang X, et al. miR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasisrelated genes. J Cancer Res Clin Oncol. 2014;140:1295-1304.
40. Iwamoto H, Kanda Y, Sejima T, et al. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol. 2014;44:53-58.
41. Jiang X, Du L, Wang L, et al. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer. 2015;136:854-862.
42. Yu DC, Li QG, Ding XW, et al. Circulating microRNAs: potential biomarkers for cancer. Int J Mol Sci. 2011;12:2055-2063.
43. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997-1006.
44. Chen ZH, Zhang GL, Li HR, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012;72:1443-1452.